University of Connecticut UConn School of Pharmacy Storrs, Connecticut
The treatment of bladder cancer has rapidly evolved over the last couple of years after decades of no new treatment options. New strategies focus on adjuvant and neoadjuvant treatment of high-risk early muscle-invasive bladder cancers, the use of maintenance therapy following adjuvant therapy of muscle-invasive bladder cancers, and the use of antibody-drug conjugates and targeted therapy options in the metastatic setting. Several ongoing clinical trials are evaluating immunotherapeutic agents, targeted agents and antibody-drug conjugates, alone or in combination with other therapies. This session is aimed to assist practitioners understand emerging management approaches and to remain up-to-date on ever changing practice recommendations.
Learning Objectives:
Apply recent and emerging data to tailor treatment regimens for patients with bladder cancer
Characterize potential biomarkers to optimize the selection of patients with bladder cancer eligible for immune checkpoint inhibitors and targeted agents
Highlight the role of the pharmacist in the treatment of patients with bladder cancer